Chronic obstructive pulmonary disease
Conditions
Interventions
One inhalation of a single-inhaler triple combination (fluticasone furoate at a dose of 100 ug, umeclidinium at a dose of 62.5 ug, and vilanterol at a dose of 25 ug) a day
continuation of dual combina
Sponsors
Shizuoka General Hospital, respiratory medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. COPD patients who are diagnosed by the criteria of GOLD guideline (FEV1/FVC <0.7) 2. Patients treated with a single-inhaler dual combination (LAMA/LABA or ICS/LABA) 3. Patients with COPD assessment test >=10 4. Patients who are satisfied following criteria a. Variable or paroxysmal symtoms b. Documented history of asthma before 40 years of age c. FeNO>35 ppb d. Documented history of perennial allergic rhinitis e. BDR of FEV1 !200 mL and 12% from baseline values f. Peripheral blood eosinophil count of >300 cells mL g. high IgE
Exclusion criteria
Exclusion criteria: 1. Patients with airway infection within 3 months 2. Patients under long term oxygen therapy 3. Patients with unstable heart disease 4. Patients who are contraindicative for fluticasone furoate, umeclidinium and vilanterol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A change of FEV1 after 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| A change of symptom score, FVC, IC, respiratory impedance, FeNO after 8 weeks | — |
Countries
Japan
Contacts
Public ContactTaisuke Akamatsu
Shizuoka General Hospital respiratory medicine
Outcome results
None listed